Supplementary Figure 7: Neutralization and binding of rVSVs bearing ebolavirus GPs or expressed ectodomains by engineered variants of mAb ADI-15946. | Nature Structural & Molecular Biology

Supplementary Figure 7: Neutralization and binding of rVSVs bearing ebolavirus GPs or expressed ectodomains by engineered variants of mAb ADI-15946.

From: Structural basis of broad ebolavirus neutralization by a human survivor antibody

Supplementary Figure 7

(a-e) Neutralization of rVSVs bearing GP from EBOV, BDBV, SUDV, TAFV, and RESTV respectively. Wild-type ADI-15946 is in black, structure-guided mutants 46M1, 46M2 and 46M3 in light, medium and dark blue, respectively. (f-h) Neutralization of rVSV bearing GPCL from EBOV, BDBV and SUDV, respectively. Neutralization of GPCL-bearing virions by wild-type ADI-15946 is in orange. Mutants 46M1-46M3 are in light to dark blue. Neutralization of virions bearing full-length GP by wild-type ADI-15946 is shown in black for comparison. (i) Antibody variants were tested for binding to soluble EBOV, BDBV (j), or SUDV (k) GP ectodomain immobilized on ELISA plates. Mutation of the neighboring ADI-15946 residue Y100A to alanine decreases binding to SUDV GPecto. (a-h) Mean±SD; n=6 biologically independent samples in each figure panel. (i-k) mean±SD; n=3 biologically independent samples in each figure panel.